On Saturday, Trump said he would impose additional sanctions against Iran in a bid to prevent the country obtaining nuclear weapons.World Politicsread more
Tensions between the U.S. and Iran will likely escalate in the near future, a former adviser to the Iranian government said on Monday.Energyread more
Chinese vice commerce minister said Monday that Beijing would like the U.S. to cancel "inappropriate" actions against Chinese companies.China Economyread more
Eldorado Resorts has agreed to merge with Caesars Entertainment in a cash and stock deal that values its peer at about $18 billion including debt, people familiar with the...Casinos and Gamingread more
A decisive win for Turkey's main opposition party in a re-run of a mayoral election in Istanbul this weekend has prompted hopes for economic and political change.Europe Politicsread more
Sixteen Asia Pacific countries have been negotiating the Regional Comprehensive Economic Partnership since 2013, with India's reluctance to open up its markets a major...Asia Economyread more
The secretary of State said he was traveling to Saudi Arabia and the United Arab Emirates to make sure that the U.S. is "strategically aligned" with its allies.Politicsread more
Experts say Facebook's cryptocurrency project Libra has been a catalyst for the price of bitcoin going higher.Technologyread more
Goldman Sachs helped state firm 1MDB to raise $6.5 billion in 2012 and 2013, and collected higher-than-typical fees of $600 million for the deals.Financeread more
Ekrem Imamoglu of the Republican People's Party beat President Tayyip Erdogan's handpicked candidate by almost 800,000 votes.World Politicsread more
Value investing has become increasingly irrelevant thanks to central banks and technology, according to AB Bernstein.Investingread more
Health care was the top issue for Americans voting in Tuesday's midterm elections.
Based on exit polls by NBC News, more U.S. voters cited it as their top concern on the ballot than any other issue — marking the first time in at least a decade that's happened.
Pascal Soriot, the CEO of European pharma giant AstraZeneca, believes that now the Democrats have won back control of the House of Representatives, they will "have to work collaboratively with the (President Donald Trump) administration.
"We will see what they come up with," he told CNBC's "Squawk Box Europe" on Thursday.
AstraZeneca is a biopharmaceutical company with a market capitalization of around $100 billion. It derives 31 percent of its product sales from the U.S.
"It is clear the (U.S.) market is under pressure, changes are coming. (It) is really hard to imagine what will happen to prices. But I think one of the things that I would say, as far as the U.S. marketplace goes, is it needs to gain transparency," Soriot said.
During the 2016 presidential campaign, Trump pledged his commitment to lowering prescription drug prices. In July 2018, the president tweeted that drugmakers "should be ashamed" for raising prices.
Democrats took control of the House in this week's midterm elections after campaigning with a health care-heavy agenda. They promised to "stop outrageous prescription drug price increases" and aim to force drug manufacturers to publicly release hard data and information justifying any significant price increase.
Trump said at a White House press conference the day after the midterms that he hopes to work together with Congressional Democrats on drug pricing. He expects the Democrats to come up with some "fantastic ideas" that he can support "including prescription drug prices" which he noted his administration has put a big dent in already.
According to the Organization for Economic Co-operation and Development (OECD), the United States had the highest per-capita pharmaceutical spending in 2015.
The Trump administration launched a BluePrint to Lower Drug Prices in May. The initiative, backed by the Department of Health and Human Services, seeks to drive down drug prices for Americans through a range of actions.
AstraZeneca itself agreed to freeze drug prices in the U.S. in July for the rest of 2018 following pressure from Trump. Pfizer, Novartis, Roche and Merck made similar commitments. The medium-term outlook for drug pricing, however, remains an open question.